FLORIDA: Gov. DeSantis introduces Evusheld a new monoclonal antibody product for pre-exposure prevention of COVID-19 thumbnail

FLORIDA: Gov. DeSantis introduces Evusheld a new monoclonal antibody product for pre-exposure prevention of COVID-19

By Dr. Rich Swier

Florida’s Governor Ron DeSantis is doing everything in his power to offer the residents of the sunshine state options to prevent, cure and fight the Covid virus.

Governor DeSantis’ newest effort include Evusheld. Evusheld is a combination of 2 monoclonal antibodies which are SARS-COV-2 spike protein-directed attachment inhibitors.

Watch:

In the below Tweet Governor DeSantis wrote, “It is authorized specifically for individuals who are immunocompromised or have a history of severe reactions to vaccines.”

According to the Evusheld website:

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product EVUSHELDTM (tixagevimab co-packaged with cilgavimab) for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and pediatric individuals (12 years of age and older weighing at least 40 kg):

  • Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and
    • Who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination or
    • For whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (e.g., severe allergic reaction) to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s).

EVUSHELD has been authorized by FDA for the emergency use described above. EVUSHELD is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19.

EVUSHELD is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of EVUSHELD under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

.@GovRonDeSantis is making COVID-19 treatments and prevention methods accessible for all Floridians, including those at risk. https://t.co/lY8tIeQRrR

— Casey DeSantis (@FLCaseyDeSantis) December 18, 2021

©Dr. Rich Swier. All rights reserved.